|
| Unit price (CNY) | Specification | Dosage | DSA | PSA | Remark |
| Cost of Drugs | ||||||
| Atezolizumab | 32,800 | 1200 mg | 1200 mg/three weeks | ±25% | GAMMA |
|
| Pemetrexed | 1733.54 | 500 mg | 500 mg/m2/three weeks | ±25% | GAMMA |
|
| Carboplatin | 30.35 | 50 mg | AUC = 6 | ±25% | GAMMA |
|
| Cisplatin | 76 | 50 mg | 75 mg/m2/three weeks | ±25% | GAMMA |
|
| Docetaxel | 910 | 20 mg | 75 mg/m2/three weeks | ±25% | GAMMA |
|
| Tislelizumab | 2180 | 100 mg | 200 mg/three weeks | ±25% | GAMMA |
|
| Cost of Disease Management | ||||||
| Outpatient clinic | 25 | every three weeks | ±25% | GAMMA | [10] | |
| Blood routine | 18 | every three weeks | ±25% | GAMMA | [11] | |
| Urine routine | 26.5 | every three weeks | ±25% | GAMMA | [11] | |
| Blood chemistry | 70 | every three weeks | ±25% | GAMMA | [11] | |
| Tumor assessment | 185 | Every 6 weeks for the first 48 weeks, then every 9 weeks | ±25% | GAMMA | [11] | |